67 - The efficacy and safety of transarterial chemoembolization combined with the different assembly of first-line targeted therapy and immunotherapy for intermediate and advanced hepatocellular carcinoma

Monday, March 31, 2025

12:10 PM – 1:10 PM CT

Location: Music City Center, Expo Poster Area

Poster Presenter(s)

XZ

Xiaoli Zhu, MD, PhD

Chief Physician
The First Affiliated Hospital of Soochow University, China (People's Republic)

Purpose: To investigate the efficacy and safety of transarterial chemoembolization (TACE) combined with the first-line targeted therapy and immunotherapy for intermediate and advanced hepatocellular carcinoma(HCC).

Materials and Methods: The clinical data of a total of 82 patients with intermediate and advanced HCC, who were admitted to the First Affiliated Hospital of Soochow University between July 2019 and March 2024, were retrospectively analyzed. The patients were divided into TACE+D+D group (n=47, receiving TACE combined with sintilimab and bevacizumab), TACE+A+T group (n=13, receiving TACE combined with atezolizumab and bevacizumab) and TACE+A+A group (n=19, receiving TACE combined with camrelizumab and apatinib). Survival curves were drawn by Kaplan-Meier method, the median overall survival (mOS) and median progression-free survival (mPFS) were compared between the three groups. According to mRECIST criterion, the objective response rate (ORR) and disease control rate (DCR) were compared between each of the three groups. The occurrences of adverse events in the three groups were recorded.

Results: The mOS and mPFS of the TACE+D+D group, the TACE+A+T group and TACE+A+A group were 19.5 months, not reached, 26.1 months, and 12.2 months, 11.3 months, and 11.1 months, respectively, with no statistically significant difference (P >0.05). The ORR and the DCR were 63.8%, 76.9n%, 89.5n%, and 95.7%, 92.3n%, 94.7n% , respectively, with no statistically significant difference (P >0.05). No statistically significant difference in the incidence of severe adverse events existed between the three groups (P=0.403). TACE combined with first-line systemic therapy has prolonged the mPFS of intermediate and advanced hepatocellular carcinoma to 11.1 months. Among the three regimens, the TACE+A+T group or the TACE+D+D group was superior in controlling the disease (12.2 months vs. 11.3 months vs. 11.1 months), but the data did not show a statistically significant difference in terms of the median PFS (P=0.928).

Conclusion:

TACE combined with the different assembly of the first-line targeted therapy and immunotherapy had marked efficacy and controllable adverse events in the treatment of intermediate and advanced HCC, which provides a potential new option for treatment of intermediate and advanced HCC. More real-world studies with larger samples will be conducted in the future to confirm the advantages and disadvantages of regimens, thus bringing better and more objective choices to patients.